MedTrace Logo

Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) Study

NCT03740425 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3235

Last updated 2019-04-18

No results posted yet for this study

Summary

Periprocedural bleeding events are frequent during transcatheter aortic valve implantation (TAVI), mainly driven by vascular complications and are associated to a worse prognosis. Therefore, red blood cell (RBC) transfusion is often required, although it is associated with worsened outcomes.

There is no consensus on the optimal transfusion strategy after bleeding. The Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) will be a multicenter retrospective registry enrolling consecutive patients who underwent TAVI; the primary aim of the study will be to test whether RBC transfusion is a marker or an independent predictor of adverse events.

Conditions

  • Transcatheter Aortic Valve Implantation (TAVI)
  • Blood Transfusion
  • AKI
  • Prognosis
  • Aortic Valve Stenosis

Interventions

PROCEDURE

Blood Transfusion

Blood Transfusion in patients who underwent transcatheter aortic valve implantation (TAVI)

Sponsors & Collaborators

  • IRCCS Policlinico S. Donato

    collaborator OTHER

  • University Hospital, Catania

    collaborator OTHER

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    collaborator OTHER

  • Hospital Clínico Universitario de Valladolid

    collaborator OTHER

  • G. d'Annunzio University

    lead OTHER

Principal Investigators

  • Marco Zimarino, MD, PhD · G. d'Annunzio University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2019-02-28
Completion
2019-03-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03740425 on ClinicalTrials.gov